How much does dietary acrylamide from fried or baked starchy foods actually raise cancer risk?
Evidence quality 4.38/5
Eight-dimension review score against the quality rubric . Each dimension scored 1–5.
- D1 Source grounding
- 5/5
- D2 Source authority
- 5/5
- D3 Arithmetic
- 4/5
- D4 Uncertainty
- 3/5
- D5 Scope
- 4/5
- D6 Prose
- 5/5
- D7 Perception honesty
- 4/5
- D8 Caveat completeness
- 5/5
Lifetime probability · lifetime, US adult
1 in 16,667
0.006% lifetime chance
Most people overestimate this.
range 1 in 1,000,000 to 1 in 1,000
● your factors — click this risk ▾ to reveal
≈ As likely as
Perceived
Acrylamide entered public consciousness in 2002, when Swedish researchers reported that high-temperature cooking of starchy foods (french fries, potato chips, coffee, bread crust) produces measurable acrylamide via the Maillard reaction between asparagine and reducing sugars. IARC subsequently classified acrylamide as Group 2A (probably carcinogenic to humans), based on strong rodent evidence. Consumer-warning regulations in California (Proposition 65) and California Acrylamide Litigation amplified the alarm. The result is a widespread perception that "browned" or "fried" carbohydrates carry a meaningful cancer risk, with consumer behavior surveys showing avoidance of toast, coffee, and french fries specifically on this basis.
Rough estimate: Many consumers treat browned/fried starchy foods as a meaningful cancer risk source
Source: editorial intuition, not polled
Actual
RR ~1.0 across most cancers; borderline RR 1.20 for kidney cancer in heaviest consumers
US adults consuming a typical Western diet (~0.4 μg/kg bw/day acrylamide intake)
Show derivation
The Pelucchi et al. 2015 updated meta-analysis (Int J Cancer, 14 cancer sites, dozens of cohort and case-control studies) concluded: "Dietary acrylamide is not related to the risk of most common cancers." The only borderline signals were kidney cancer (RR 1.20, 95% CI 1.00-1.45) and endometrial and ovarian cancer in never-smokers (RR 1.23 and 1.39 respectively). EFSA's 2015 Scientific Opinion computed Margins of Exposure (MOEs) of 425 for the average general-population intake against the neoplastic effects benchmark dose, flagging dietary acrylamide as a public-health concern in principle without quantifying attributable human cancer cases. The native rate of 1 in 10,000 lifetime attributable cases is computed from the borderline kidney-cancer signal: US baseline lifetime kidney cancer risk is approximately 2.1% (SEER); applying RR 1.20 to the upper-intake quartile gives an absolute increase of roughly 0.4 percentage points, but the population-average effect is much smaller because most adults are not in the top quartile. The lifetime figure of 6 in 100,000 is a conservative average-adult estimate; the high end of the uncertainty band captures the heaviest dietary exposure subgroup.
Caveats: Dietary acrylamide is genuinely genotoxic in rodents and IARC-classified as Grou…
Dietary acrylamide is genuinely genotoxic in rodents and IARC-classified as Group 2A (probably carcinogenic to humans). The translation to typical human dietary exposure is the contested step. The Pelucchi 2015 meta-analysis examined 14 cancer sites across dozens of cohorts and found no consistent association; only kidney cancer reached borderline significance in the highest-exposure quintile, with endometrial and ovarian signals emerging only in never-smokers. EFSA's MOE of 425 is a regulatory flag (below the 10,000 threshold typically used for genotoxic carcinogens) and motivates voluntary food-industry reductions, but EFSA does not quantify attributable human cancer cases. The normalized 6-in-100,000 estimate is a conservative population-average attribution; the heavy-consumer subgroup may experience risk closer to the high end of the uncertainty band. Tobacco smoke dominates total acrylamide exposure for smokers, and the dietary signal cannot be cleanly separated from smoking-related cancer in cohort data. Surveillance gaps: dietary acrylamide intake is hard to estimate from food-frequency questionnaires because acrylamide content varies dramatically with cooking time and temperature for the same food.
Regional breakdown
The headline figure averages across very different populations. Here’s how the probability varies by geography or context:
| Region / context | Lifetime probability | Notes |
|---|---|---|
| US adult (typical Western diet, average acrylamide exposure) | 1 in 16,667 |
Population-average attributable risk; well below the kidney-cancer borderline signal in Pelucchi 2015 |
| Heavy-fried-food consumer (top dietary intake quartile) | 1 in 2,500 |
Pelucchi 2015 top-quartile kidney cancer RR 1.20 applied to SEER baseline 2.1% gives ~0.4% absolute lifetime risk for kidney cancer specifically |
| Current smoker (cigarette acrylamide intake) | 1 in 1,000 |
Tobacco smoke is the dominant acrylamide source for smokers, delivering 3-5x dietary intake; the cancer signal is dominated by other tobacco carcinogens |
Risks at similar odds
Other risks with roughly the same likelihood — useful for calibration.
Charred meat & cancer
How much does eating charred or well-done grilled meat actually raise your cancer risk?
Glyphosate & cancer
What are the odds that dietary glyphosate (Roundup) exposure will give you cancer?
Red meat & CRC
How much does eating red or processed meat every day actually raise your colorectal cancer risk?
Infection from shared drink
What are the odds of catching a meaningful infection from sharing a drink bottle or cup?
Unsupervised infant choking
What are the odds of a choking emergency if an infant eats unsupervised?
Recently viewed on this device
Stored locally — clear anytime.
Pick challenger
The normalized lifetime attributable cancer risk from typical dietary acrylamide sits at roughly 6 in 100,000 — a conservative population-average estimate against a baseline US adult lifetime cancer risk from all causes of about 39.4%. The Pelucchi et al. 2015 updated meta-analysis examined 14 cancer sites across dozens of cohort and case-control studies and concluded that “dietary acrylamide is not related to the risk of most common cancers.” Only kidney cancer reached borderline statistical significance (RR 1.20, 95% CI 1.00-1.45) in the highest-intake quintile, with endometrial and ovarian signals appearing only in never-smokers. NCI’s position is the same: “A large number of epidemiologic studies in humans have found no consistent evidence that dietary acrylamide exposure is associated with the risk of any type of cancer.”
The gap between perception and evidence has a familiar shape. Acrylamide is unambiguously genotoxic in rodents at the doses used in carcinogenicity bioassays, and IARC classified it as Group 2A (probably carcinogenic) on that basis. EFSA’s 2015 Scientific Opinion computed a Margin of Exposure of 425 between typical adult intake and the neoplastic effects benchmark dose, which is below the 10,000 threshold EFSA uses to flag regulatory concern for genotoxic carcinogens. That flag motivated voluntary food-industry reductions (Codex Code of Practice, FDA action plan, EU benchmark levels) but does not translate to a quantified human cancer attribution. The translation is the missing step: rodent carcinogenesis at high doses does not consistently produce a population-level human cancer signal at typical dietary doses, and the cohorts agree on this.
Where the number doesn’t apply cleanly: tobacco smoke is the dominant acrylamide exposure source for smokers, delivering 3-5x dietary intake, and the attributable cancer effect is folded into the well-documented smoking-cancer signal. People eating french fries, chips, or heavily browned baked goods daily fall in the top dietary intake quartile and pick up the borderline kidney-cancer signal Pelucchi 2015 reported; the absolute lifetime increment for that subgroup is still small relative to baseline. Chronic kidney disease prolongs acrylamide and glycidamide retention at the same dietary intake. For most adults the meaningful cancer-prevention dietary levers remain weight, alcohol, fiber, and red-meat frequency, not whether the toast or coffee crossed into deep brown.
Claim ledger
Every number below is what each source reported, with the verbatim quote we relied on and how we arrived at our figure. Click any link to verify directly.
-
[1] European Food Safety Authority — Acrylamide in food: EFSA position
Acrylamide in food: EFSA position- Statistic
Acrylamide in food potentially increases cancer risk in all age groups; human evidence limited and inconsistent- Excerpt
“"Acrylamide in food potentially increases the risk of developing cancer for consumers in all age groups. Studies on laboratory animals have shown that exposure to acrylamide through the diet increased the likelihood of developing gene mutations and tumours in various organs. Studies on human subjects have provided limited and inconsistent evidence of increased risk of developing cancer." ”
- Source data from
- 2015-06-04
- Accessed
- 2026-05-30 · archived copy
- Calculation
- EFSA's 2015 Scientific Opinion (EFSA Journal 2015;13(6):4104) computed Margins of Exposure (MOE) of 425 for the average adult dietary intake against the neoplastic effects benchmark dose (BMDL10 = 0.17 mg/kg bw/day). MOE values below 10,000 are typically flagged by EFSA as a public-health concern for genotoxic carcinogens, which is why dietary acrylamide is listed as a regulatory priority despite the inconsistent human epidemiology. The position statement deliberately avoids quantifying attributable human cancer cases because the human evidence is too weak; the regulatory action is mitigation-oriented (reducing food levels), not risk-quantifying.
- Independence
- EFSA's evaluation is the European regulatory counterpart to FDA action plans. Both agencies synthesize the same underlying epidemiology (Mucci, Hogervorst, Pelucchi cohorts) but make independent policy judgments.
-
[2] International Journal of Cancer / Pelucchi, Bosetti, Galeone, La Vecchia — Dietary acrylamide and cancer risk: an updated meta-analysis
Dietary acrylamide and cancer risk: an updated meta-analysis- Statistic
Dietary acrylamide not associated with risk of most cancers; borderline RR 1.20 (95% CI 1.00-1.45) for kidney cancer- Excerpt
“"Dietary acrylamide is not related to the risk of most common cancers. A modest association for kidney cancer, and for endometrial and ovarian cancers in never smokers only, cannot be excluded." ”
- Source data from
- 2015-06-15
- Accessed
- 2026-05-30 · archived copy
- Calculation
- Pelucchi 2015 covered 14 cancer sites across dozens of cohort and case-control studies. The pooled relative risks clustered near 1.0 for nearly every cancer examined. Only kidney cancer reached borderline significance (RR 1.20, 95% CI 1.00-1.45) for the highest dietary acrylamide quintile vs the lowest. Endometrial and ovarian cancers showed borderline associations in the never-smoker subgroup only. This is the load- bearing source for framing dietary acrylamide as low-risk at typical intake: the epidemiology examined the largest cancer sites and found no consistent signal. The EFSA Margin of Exposure calculation is consistent with this: the MOE of 425 is a regulatory flag, not a measured human cancer attribution.
- Independence
- Pelucchi et al. 2015 updates their 2011 review (Ann Oncol 22:1487-1499, PMID 21239401) with additional prospective cohorts. Methodologically independent from EFSA's regulatory toxicology evaluation.
-
[3] National Cancer Institute (NIH) — Acrylamide and Cancer Risk
Acrylamide and Cancer Risk- Statistic
Large number of epidemiologic studies in humans found no consistent evidence that dietary acrylamide is associated with the risk of any type of cancer- Excerpt
“"A large number of epidemiologic studies (both case-control and cohort studies) in humans have found no consistent evidence that dietary acrylamide exposure is associated with the risk of any type of cancer." Acrylamide develops when "vegetables that contain the amino acid asparagine, such as potatoes, are heated to high temperatures in the presence of certain sugars." ”
- Source data from
- 2017-12-05
- Accessed
- 2026-05-30 · archived copy
- Calculation
- NCI's position is the US-side complement to EFSA's evaluation. NCI explicitly notes that the NTP classification (acrylamide is "reasonably anticipated to be a human carcinogen") is based primarily on rodent studies, not human evidence. The fact sheet states unambiguously that human epidemiology has not found a consistent dietary cancer link. This is the basis for treating cookware-derived acrylamide as a regulatory- precaution issue rather than a meaningful personal cancer risk at typical intake.
- Independence
- NCI synthesis is methodologically distinct from Pelucchi meta-analysis; NCI relies on the full body of NIH-AARP and other US cohort data plus international evidence compilations.